FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311451841> ?p ?o ?g. }

• W4311451841 endingPage "126" @default.
• W4311451841 startingPage "112" @default.
• W4311451841 abstract "In clinical practice guidelines there is no consensus about the medications that should be initially offered to children and young people with Tourette's syndrome. To provide a rigorous evidence base that could help guide decision making and guideline development, we aimed to compare the efficacy, tolerability, and acceptability of pharmacological interventions for Tourette's syndrome.For this systematic review and network meta-analysis, we searched the Cochrane Central Register of Controlled Trials, Embase, PsycINFO, PubMed, Web of Science, the WHO International Clinical Trials Registry Platform, and ClinicalTrials.gov, for published and unpublished studies from database inception to Nov 19, 2021. We included double-blind randomised controlled trials of any medication administered as a monotherapy for at least 1 week against another medication or placebo in children and adolescents (aged ≥4 years and ≤18 years), adults (>18 years), or both, diagnosed with Tourette's syndrome according to standardised criteria. We excluded studies that exclusively recruited participants with comorbid attention-deficit hyperactivity disorder or obsessive-compulsive disorder. The primary outcome was change in severity of tic symptoms (efficacy). Secondary outcomes were treatment discontinuations due to adverse events (tolerability) and for any reason (acceptability). Pharmacological interventions were examined considering medication categories and medications individually in separate analyses. Summary data were extracted and pooled with a random-effects network meta-analysis to calculate standardised mean differences for efficacy and odds ratios for tolerability and acceptability, with 95% CIs. The Confidence in Network Meta-Analysis (CINeMA) framework was used to assess the certainty of evidence. The protocol was pre-registered in PROSPERO (CRD42022296975).Of the 12 088 records identified through the database search, 88 records representing 39 randomised controlled trials were included in the network meta-analysis; these 39 randomised controlled trials comprised 4578 participants (mean age 11·8 [SD 4·5] years; 3676 [80·8%] male participants) and evaluated 23 individual medications distributed across six medication categories. When considering medication categories, first-generation (standardised mean difference [SMD] -0·65 [95% CI -0·79 to -0·51]; low certainty of evidence) and second-generation (-0·71 [-0·88 to -0·54]; moderate certainty of evidence) antipsychotic drugs, as well as α-2 agonists (-0·21 [-0·39 to -0·03]; moderate certainty of evidence), were more efficacious than placebo. First-generation and second-generation antipsychotic drugs did not differ from each other (SMD 0·06 [95% CI -0·14 to 0·25]; low certainty of evidence). However, both first-generation (SMD 0·44 [95% CI 0·21 to 0·66]) and second-generation (0·49 [0·25 to 0·74]) antipsychotic drugs outperformed α-2 agonists, with moderate certainty of evidence. Similar findings were observed when individual medications were considered: aripiprazole (SMD -0·60 [95% CI -0·83 to -0·38]), haloperidol (-0·51 [-0·88 to -0·14]), olanzapine (-0·83 [-1·49 to -0·18]), pimozide (-0·48 [-0·84 to -0·12]), risperidone (-0·66 [-0·98 to -0·34]), and clonidine (-0·20 [-0·37 to -0·02]) all outperformed placebo, with moderate certainty of evidence. Antipsychotic medications did not differ from each other, but there was low to very low certainty of evidence for these comparisons. However, aripiprazole (SMD -0·40 [95% CI -0·69 to -0·12]) and risperidone (-0·46 [-0·82 to -0·11]) outperformed clonidine, with moderate certainty of evidence. Heterogeneity or inconsistency only emerged for a few comparisons. In terms of tolerability and acceptability, there were no relevant findings for any of the efficacious medication categories or individual medications against each other or placebo, but there was low to very low certainty of evidence associated with these comparisons.Our analyses show that antipsychotic drugs are the most efficacious intervention for Tourette's syndrome, while α-2 agonists are also more efficacious than placebo and could be chosen by those who elect not to take antipsychotic drugs. Shared decision making about the degree of tic-related severity and distress or impairment, the trade-offs of efficacy and safety between antipsychotic drugs and α-2 agonists, and other highly relevant individual factors that could not be addressed in the present analysis, should guide the choice of medication for children and young people with Tourette's syndrome.None." @default.
• W4311451841 created "2022-12-26" @default.
• W4311451841 creator A5011291875 @default.
• W4311451841 creator A5030875369 @default.
• W4311451841 creator A5043592614 @default.
• W4311451841 creator A5060512263 @default.
• W4311451841 creator A5064627383 @default.
• W4311451841 creator A5080720807 @default.
• W4311451841 creator A5087713261 @default.
• W4311451841 date "2023-02-01" @default.
• W4311451841 modified "2023-10-16" @default.
• W4311451841 title "Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: a systematic review and network meta-analysis" @default.
• W4311451841 cites W120122032 @default.
• W4311451841 cites W1499453506 @default.
• W4311451841 cites W1617328014 @default.
• W4311451841 cites W1964162160 @default.
• W4311451841 cites W1991043200 @default.
• W4311451841 cites W1995777506 @default.
• W4311451841 cites W2001633786 @default.
• W4311451841 cites W2001900074 @default.
• W4311451841 cites W2003772299 @default.
• W4311451841 cites W2003790674 @default.
• W4311451841 cites W2008219589 @default.
• W4311451841 cites W2009158769 @default.
• W4311451841 cites W2015540486 @default.
• W4311451841 cites W2019004683 @default.
• W4311451841 cites W2019101336 @default.
• W4311451841 cites W2032299959 @default.
• W4311451841 cites W2033074878 @default.
• W4311451841 cites W2036284238 @default.
• W4311451841 cites W2050751727 @default.
• W4311451841 cites W2050973084 @default.
• W4311451841 cites W2066617645 @default.
• W4311451841 cites W2070859754 @default.
• W4311451841 cites W2072970041 @default.
• W4311451841 cites W2075046475 @default.
• W4311451841 cites W2079249609 @default.
• W4311451841 cites W2088550173 @default.
• W4311451841 cites W2095726969 @default.
• W4311451841 cites W2096989547 @default.
• W4311451841 cites W2111999709 @default.
• W4311451841 cites W2119615820 @default.
• W4311451841 cites W2119753690 @default.
• W4311451841 cites W2121594817 @default.
• W4311451841 cites W2121769610 @default.
• W4311451841 cites W2121796373 @default.
• W4311451841 cites W2127009052 @default.
• W4311451841 cites W2129821518 @default.
• W4311451841 cites W2130773639 @default.
• W4311451841 cites W2131701504 @default.
• W4311451841 cites W2132119658 @default.
• W4311451841 cites W2153846694 @default.
• W4311451841 cites W2342520078 @default.
• W4311451841 cites W2412768561 @default.
• W4311451841 cites W2418813771 @default.
• W4311451841 cites W2495235786 @default.
• W4311451841 cites W2569405360 @default.
• W4311451841 cites W2726321932 @default.
• W4311451841 cites W2738387807 @default.
• W4311451841 cites W2805741406 @default.
• W4311451841 cites W2811372873 @default.
• W4311451841 cites W2886298463 @default.
• W4311451841 cites W2889881994 @default.
• W4311451841 cites W2890157050 @default.
• W4311451841 cites W2912141202 @default.
• W4311451841 cites W2943985522 @default.
• W4311451841 cites W2944778893 @default.
• W4311451841 cites W2961166869 @default.
• W4311451841 cites W2975424845 @default.
• W4311451841 cites W3015163167 @default.
• W4311451841 cites W3015809125 @default.
• W4311451841 cites W3023350371 @default.
• W4311451841 cites W3023958087 @default.
• W4311451841 cites W3053835967 @default.
• W4311451841 cites W3103025157 @default.
• W4311451841 cites W3114288587 @default.
• W4311451841 cites W3204636898 @default.
• W4311451841 cites W3206336443 @default.
• W4311451841 cites W3214084045 @default.
• W4311451841 cites W4207065575 @default.
• W4311451841 cites W4213288886 @default.
• W4311451841 cites W4289313637 @default.
• W4311451841 doi "https://doi.org/10.1016/s2352-4642(22)00316-9" @default.
• W4311451841 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36528030" @default.
• W4311451841 hasPublicationYear "2023" @default.
• W4311451841 type Work @default.
• W4311451841 citedByCount "3" @default.
• W4311451841 countsByYear W43114518412023 @default.
• W4311451841 crossrefType "journal-article" @default.
• W4311451841 hasAuthorship W4311451841A5011291875 @default.
• W4311451841 hasAuthorship W4311451841A5030875369 @default.
• W4311451841 hasAuthorship W4311451841A5043592614 @default.
• W4311451841 hasAuthorship W4311451841A5060512263 @default.
• W4311451841 hasAuthorship W4311451841A5064627383 @default.
• W4311451841 hasAuthorship W4311451841A5080720807 @default.
• W4311451841 hasAuthorship W4311451841A5087713261 @default.
• W4311451841 hasConcept C118552586 @default.
• W4311451841 hasConcept C126322002 @default.

• next